看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 0.2x - 0.2x | 0.2x |
| Selected Fwd Ps Multiple | 0.1x - 0.1x | 0.1x |
| Fair Value | $3.71 - $4.10 | $3.90 |
| Upside | 74.1% - 92.4% | 83.2% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Moderna, Inc. | - | NasdaqGS:MRNA |
| Regeneron Pharmaceuticals, Inc. | - | NasdaqGS:REGN |
| Gilead Sciences, Inc. | - | NasdaqGS:GILD |
| Amgen Inc. | - | NasdaqGS:AMGN |
| Dyadic International, Inc. | - | NasdaqCM:DYAI |
| Sunshine Biopharma, Inc. | - | NasdaqCM:SBFM |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| MRNA | REGN | GILD | AMGN | DYAI | SBFM | |||
| NasdaqGS:MRNA | NasdaqGS:REGN | NasdaqGS:GILD | NasdaqGS:AMGN | NasdaqCM:DYAI | NasdaqCM:SBFM | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 122.0% | 16.7% | 5.1% | 7.4% | 17.5% | NM- | ||
| 3Y CAGR | -44.0% | -4.0% | 1.7% | 8.8% | 21.9% | 596.2% | ||
| Latest Twelve Months | -52.7% | 8.3% | 6.0% | 18.6% | 13.8% | 61.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -89.6% | 38.3% | 12.3% | 23.7% | -420.6% | -3018.1% | ||
| Prior Fiscal Year | -68.8% | 30.1% | 20.9% | 23.8% | -332.2% | -615.4% | ||
| Latest Fiscal Year | -110.0% | 31.1% | 1.7% | 12.2% | -234.4% | -18.7% | ||
| Latest Twelve Months | -110.0% | 31.1% | 1.7% | 12.2% | -188.1% | -12.8% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -1.0x | 11.5x | 11.3x | 13.8x | NA | 1.5x | ||
| Price / LTM Sales | 3.9x | 4.8x | 4.7x | 5.0x | 11.7x | 0.1x | ||
| LTM P/E Ratio | -3.5x | 15.5x | 283.3x | 40.5x | -6.2x | -1.0x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 3.9x | 4.8x | 11.7x | |||||
| Historical LTM P/S Ratio | 0.3x | 29.4x | 176.7x | |||||
| Selected Price / Sales Multiple | 0.2x | 0.2x | 0.2x | |||||
| (x) LTM Sales | 33 | 33 | 33 | |||||
| (=) Equity Value | 7 | 8 | 8 | |||||
| (/) Shares Outstanding | 2.0 | 2.0 | 2.0 | |||||
| Implied Value Range | 3.71 | 3.90 | 4.10 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 3.71 | 3.90 | 4.10 | 2.13 | ||||
| Upside / (Downside) | 74.1% | 83.2% | 92.4% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | MRNA | REGN | GILD | AMGN | DYAI | SBFM | |
| Value of Common Equity | 13,087 | 67,869 | 134,360 | 164,847 | 41 | 4 | |
| (/) Shares Outstanding | 386.6 | 107.0 | 1,245.3 | 537.2 | 29.6 | 2.0 | |
| Implied Stock Price | 33.85 | 634.14 | 107.89 | 306.86 | 1.38 | 2.13 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 33.85 | 634.14 | 107.89 | 306.86 | 1.38 | 2.13 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |